Aspira Women's Health

Aspira Women's Health is a diagnostic company specializing in AI-powered testing solutions for gynecologic care, with a focus on ovarian cancer risk stratification. The company develops and commercializes non-invasive biomarker-based tests for evaluating adnexal masses and personalizing ovarian cancer risk assessment. Their primary product portfolio, OvaSuite, includes OvaWatch (longitudinal monitoring for indeterminate/benign adnexal masses with reported >99% negative predictive value) and Ova1Plus (reflex testing combining biomarkers including CA-125, menopausal status, and ultrasound findings for surgical management decisions). Ova1Plus employs a two-step algorithm: Ova1 is performed first, and if intermediate risk is detected, Overa is automatically performed for increased specificity. Clinical evidence shows Ova1 detected malignancy risk in early-stage and premenopausal/postmenopausal cases where CA-125 was uninformative. The company emphasizes research-driven development with peer-reviewed publications supporting clinical utility. Products are FDA-cleared and positioned for use in conjunction with imaging and clinical assessment, not as standalone screening tools. Aspira targets obstetricians/gynecologists, gynecologic oncologists, primary care physicians, and hospital laboratories managing patients with adnexal masses.